We are live on !
Find out more
Steve Schonfeld Schonfeld Strategic Advisors
AUM
$27.9B
Turnover
53.32%
1-Year Est. Return
51.18%
Steve Schonfeld is the founder of Schonfeld Strategic Advisors, a multi-manager investment firm with roots in proprietary trading. Schonfeld allocates capital across quantitative and discretionary strategies with an emphasis on risk controls and diversification of return streams. The firm is a major name in the multi-strategy hedge fund landscape.
This Fund
S&P 500
This Quarter Est. Return
+28.16%
1 Year Est. Return
+51.18%
3 Year Est. Return
+146.2%
5 Year Est. Return
+181.83%
10 Year Est. Return
+1,058.56%
AUM
$27.9B
AUM Growth
+$13.7B
(+96%)
Cap. Flow
+$4.81B
Cap. Flow % of AUM
Cap. Flow %
17.26%
Top 10 Holdings %
Top 10 Hldgs %
28.91%
Holding
3,207
New
1,059
Increased
750
Reduced
650
Closed
651
Avg Time Held
Equity + Options
0.7
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$689M |
| 2 |
NVIDIA
NVDA
|
+$475M |
| 3 |
iShares MSCI Brazil ETF
EWZ
|
+$350M |
| 4 |
Microsoft
MSFT
|
+$347M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$262M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$185M |
| 2 |
Meta Platforms (Facebook)
META
|
+$131M |
| 3 |
Arm
ARM
|
+$91.4M |
| 4 |
CRH
CRH
|
+$78.5M |
| 5 |
Unity
U
|
+$69.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 47.11% |
| 2 | Technology | 15.09% |
| 3 | Industrials | 9.5% |
| 4 | Financials | 7.56% |
| 5 | Consumer Discretionary | 5.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2276
Diversified Healthcare Trust
DHC
$1.74B
| $119K | ﹤0.01% |
+12,768
| New | +$105K |
2026 Q2
0 quarters
|
|
2277
Lexicon Pharmaceuticals
LXRX
$797M
| $119K | ﹤0.01% |
49,435
-25,675
| -34% | -$50K |
2024 Q1
9 quarters
|
|
2278
Newell Brands
NWL
$2.46B
| $118K | ﹤0.01% |
+19,172
| New | +$81.1K |
2026 Q2
0 quarters
|
|
2279
Auna
AUNA
$341M
| $118K | ﹤0.01% |
+22,944
| New | +$116K |
2026 Q2
0 quarters
|
|
2280
DMC Global
BOOM
$157M
| $117K | ﹤0.01% |
+20,078
| New | +$131K |
2026 Q2
0 quarters
|
|
2281
Conduent
CNDT
$195M
| $116K | ﹤0.01% |
79,396
+4,701
| +6% | +$7.3K |
2025 Q2
4 quarters
|
|
2282
FS KKR Capital
FSK
$3.2B
| $114K | ﹤0.01% |
10,884
-89,936
| -89% | -$967K |
2025 Q4
2 quarters
|
|
2283
Bloomin' Brands
BLMN
$878M
| $114K | ﹤0.01% |
12,489
-15,478
| -55% | -$113K |
2026 Q1
1 quarter
|
|
|
NHICW
2284
DELISTED
NewHold Investment Corp III Warrants
NHICW
| $114K | ﹤0.01% |
55,000
-25,000
| -31% | -$36.4K |
2025 Q2
4 quarters
|
|
2285
Janus International
JBI
$470M
| $113K | ﹤0.01% |
20,410
-58
| -0.3% | -$304 |
2026 Q1
1 quarter
|
|
2286
Beyond Meat
BYND
$101M
| $111K | ﹤0.01% |
+4,947
| New | +$115K |
2026 Q2
0 quarters
|
|
2287
Solmate Infrastructure Public Limited Company Class B Ordinary Shares
SLMT
$35.4M
| $111K | ﹤0.01% |
21,922
-61,144
| -74% | -$398K |
2025 Q4
2 quarters
|
|
2288
Evolent Health
EVH
$541M
| $111K | ﹤0.01% |
20,447
-42,896
| -68% | -$164K |
2026 Q1
1 quarter
|
|
2289
Fabric.AI Inc
FABC
$11.7M
| $111K | ﹤0.01% |
+30,000
| New | +$108K |
2026 Q2
0 quarters
|
|
2290
Allogene Therapeutics
ALLO
$290M
| $110K | ﹤0.01% |
+53,079
| New | +$117K |
2026 Q2
0 quarters
|
|
2291
eGain
EGAN
$157M
| $110K | ﹤0.01% |
17,407
+1,193
| +7% | +$8.75K |
2026 Q1
1 quarter
|
|
2292
Treace Medical Concepts
TMCI
$336M
| $109K | ﹤0.01% |
+27,277
| New | +$75K |
2026 Q2
0 quarters
|
|
2293
Perion Network
PERI
$369M
| $108K | ﹤0.01% |
+11,149
| New | +$106K |
2026 Q2
0 quarters
|
|
2294
Array Technologies
ARRY
$750M
| $108K | ﹤0.01% |
+14,562
| New | +$116K |
2026 Q2
0 quarters
|
|
2295
Altimmune
ALT
$323M
| $107K | ﹤0.01% |
+35,077
| New | +$105K |
2026 Q2
0 quarters
|
|
2296
Byrna Technologies
BYRN
$89.2M
| $107K | ﹤0.01% |
15,881
+1,287
| +9% | +$7.91K |
2026 Q1
1 quarter
|
|
2297
Ocular Therapeutix
OCUL
$1.37B
| $105K | ﹤0.01% |
+10,711
| New | +$97.1K |
2026 Q2
0 quarters
|
|
2298
Obsidian Energy
OBE
$645M
| $105K | ﹤0.01% |
12,888
-26,984
| -68% | -$303K |
2025 Q4
2 quarters
|
|
2299
Entera Bio
ENTX
$545M
| $104K | ﹤0.01% |
58,871
+3,648
| +7% | +$4.56K |
2024 Q2
8 quarters
|
|
2300
Cantor Equity Partners VI
CEPS
$149M
| $104K | ﹤0.01% |
10,000
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
Steve Schonfeld's Q2 2026 Portfolio in Review
As of Q2 2026, Steve Schonfeld held 3,207 positions worth $27.9B, up 96% from $14.2B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Steve Schonfeld deployed $4.81B of net new capital in Q2 2026, opening 1,059 new positions and adding to 750 existing holdings. Its largest new stake was iShares MSCI Brazil ETF: 9,366,387 shares worth $323M.
By sector, the portfolio is most concentrated in Miscellaneous at 47% of assets, up from 34% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $185M trimmed.
- Steve Schonfeld's largest Q2 2026 buy was iShares MSCI Brazil ETF: 9,366,387 shares worth $323M.
- Steve Schonfeld added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $689M increase.
- Steve Schonfeld's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $185M.
- Steve Schonfeld fully exited Marvell Technology in Q2 2026, selling an estimated $60.3M.
- Steve Schonfeld's ten largest holdings make up 29% of its $27.9B portfolio in Q2 2026.
- Steve Schonfeld opened 1,059 new positions and closed 651 in Q2 2026.
- Steve Schonfeld's portfolio value rose 96% quarter-over-quarter to $27.9B.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.